Prota Therapeutics

Executive Summary

Prota Therapeutics is an Australian biotech company advancing a novel oral immunotherapy platform for food allergies, with its lead candidate PRT120 targeting peanut allergy. The platform, exclusively licensed from the Murdoch Children’s Research Institute, is designed to induce long-lasting desensitization and improve quality of life for allergy sufferers. PRT120 is currently positioned for a pivotal Phase 3 trial, addressing a significant unmet need as peanut allergy affects millions worldwide and there are limited approved treatments. The company has raised $31 million to date and operates as a private entity with 50-200 employees. Prota’s approach differentiates from existing therapies by aiming for sustained protection rather than acute reaction management, potentially capturing a large market share in the allergy immunotherapy space. Prota faces typical biotech risks including clinical trial outcomes, regulatory hurdles, and competitive dynamics in the allergy space. However, the strong intellectual property backed by a reputable research institute and the large addressable market provide a solid foundation. With Phase 3 initiation on the horizon, the next 12-18 months are critical for demonstrating efficacy and safety. A successful trial could lead to licensing deals or a significant funding round to support commercialization. The company’s private status offers flexibility but also limits visibility; upcoming catalysts will be key to unlocking value.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Pivotal Phase 3 Trial for PRT12075% success
• Q4 2026Strategic Partnership or Licensing Agreement40% success
• Q2 2027Series B/C Financing Round60% success